NOS3 and chronic obstructive pulmonary disease: Based on previous evidence of dysregulation in the NO pathway in COPD (10, 11), we hypothesized that serum levels of NO-related biomarkers (ADMA, NO, and eNOS) differ between healthy individuals, patients with stable COPD, and those with acute exacerbations, and may serve as diagnostic indicators of disease stage.